The medication may represent a new treatment option for dialysis patients, researchers concluded.
Investigators found that dialysis patients with serum calcium levels of 10.2 mg/dL or greater had increased risks of premature death.
Higher magnesium levels in hemodialysis patients with high phosphorus levels were associated with decreased cardiovascular mortality.
Use of these agents is associated with a much lower incidence of hypercalcemia compared with the use of calcium carbonate or calcium acetate.
Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.
In adjusted analyses, serum phosphorus levels independently predicted glucose disposal rate.
Each 0.5 mg/dL increment in serum phosphorus associated with 58% increased odds of coronary heart failure (CHF).
Rates for infection-, gastrointestinal-, and cardiac-related adverse events are lower than with sevelamer carbonate or calcium acetate.
Plant-based diet had the lowest urinary phosphorus excretion, whereas an inorganic-based diet had the highest.
Researchers observe significant decline in serum phosphate levels with 6 hours vs. 4 hours of treatment.
No association between phosphorus levels and all-cause mortality in women.
Every 1 mg/dL increase in serum phosphorus was independently associated with a 36% increased relative risk of kidney failure.
Study of coronary artery calcification (CAC) risk also shows serum phosphorus levels associated with nutritional intake and dialysis adequacy.
In addition to reducing serum phosphorus levels to within the recommended range, ferric citrate increases iron stores.
In a study, PA21 was as efficacious as sevelamer carbonate, but patients taking PA21 had a lower pill burden and better adherence.
Researchers observed the association among individuals with serum phosphorus levels measured after fasting for 12 or more hours.
Use is associated with fewer hospitalizations versus sevelamer carbonate and calcium acetate.
In mice with and without CKD, phosphorus levels decreased by an average of 35% by 6 hours after injection with long-acting PTH.
Protein levels found to modify the effect of serum phosphorus with mortality in hemodialysis patients.
Researchers compared the novel iron-based phosphate binder with sevelamer.
In a study, nurses and technicians educated groups of hemodialysis patients about phosphate binders.
Researchers tested an intervention that included an educational fair, phosphorus group social, and staff education on phosphate binders.
Researchers observed reduced phosphorus levels in HD patients whose diet restricted intake of phosphorus additives.
Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Calcium-based and non-calcium-based binder use were associated with similar death risks.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Vascular calcification contributes to increased cardiovascular risk in dialysis patients.
New findings are consistent with those from previous animal studies.
PA21 comparable in safety and efficacy to sevelamer carbonate out to 52 weeks, study finds.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)